Innovation in radiotherapy promises better treatment of AML

31 October 2022
actinium_large

Targeted radiotherapy firm Actinium Pharmaceuticals (NYSE: ATNM) has announced positive top-line results from the Phase III SIERRA study.

Shares in the company are up more than 70% from last week, with the results showing the trial of its lead product candidate, Iomab-B, met its primary endpoint of durable complete remission in acute myeloid leukemia (AML).

The multicenter study compares Iomab-B as a conditioning regimen prior to a bone marrow transplant (BMT), versus a control arm which allows all current means of conventional care.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical